Kolexia
Mezquita Perez Laura Oncologie médicale
Mezquita Perez Laura
Oncologie médicale
Gustave-Roussy
Villejuif, France
488 Activités
1.7 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale Carcinomes Adénocarcinome pulmonaire Alcoolisme Adénocarcinome Carcinome épidermoïde

Collaborateurs

Voir plus
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Planchard David
Planchard David
Gustave-Roussy, Villejuif, France
Auclin Edouard
Auclin Edouard
Hôpital Européen Georges Pompidou, Paris, France
Caramella Caroline
Caramella Caroline
Gh Paris Site Saint Joseph, Paris, France

Industries

Voir plus
Roche
1 collaboration(s)
Dernière en 2022
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
ACCELERATE: Accelerating Lung Cancer Diagnosis Through Liquid Biopsy
Essai Clinique (University Health Network, Toronto)   08 mars 2024
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.
Therapeutic advances in medical oncology   06 mars 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
British journal of cancer   04 janvier 2024
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Clinical lung cancer   22 novembre 2023
IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLC.
Med (New York, N.Y.)   20 novembre 2023
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
Journal of thoracic disease   05 novembre 2023
1508TiP The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1450P Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   18 septembre 2023